Google’s AI Dilemma – Bard’s Promise Versus Ethical Concerns

Alphabet Inc (NASDAQ: GOOG) (NASDAQ: GOOGL) Google and Discord Inc have been hosting an exclusive chat for avid users of Bard, Google's AI-powered chatbot. 

Alphabet Inc (NASDAQ:GOOG) (NASDAQ:GOOGLGoogle and Discord Inc have been hosting an exclusive chat for avid users of Bard, Google’s AI-powered chatbot. 

This platform has become a ground for open discussions among Google’s product managers, designers, and engineers, evaluating Bard’s performance and questioning the value derived from the substantial resources allocated to its development.

Also Read: Google, Nvidia Collaborate On AI Expansion In Strategic Play Against Microsoft

Senior product manager for Bard, Dominik Rabiej, expressed skepticism about the reliability of large language models (LLMs). He emphasized the need for independent verification of LLM outputs, a sentiment echoed by other Google employees, Bloomberg reports.

Integrating Bard into core Google services like Gmail, Maps, Docs, and YouTube has not been without challenges. 

Users have raised concerns about the AI tool generating inaccurate information and potentially hazardous advice. 

In response, Google introduced a search button on Bard to allow users to validate the AI-generated responses against Google’s search engine results.

There have also been criticisms regarding the working conditions of contractors training Bard. The rapid development and deployment of AI technologies like Bard have raised ethical concerns. 

Google allegedly sidelined these issues to compete with AI innovations from companies like OpenAI Inc and others in the tech industry.

With Google’s search functionality generating a significant portion of Alphabet’s revenue, the success of Bard is crucial. 

The rise of generative AI technologies threatens Google’s dominance in the search market, making the development and refinement of Bard a strategic priority for the tech giant.

Price Action: GOOG shares are trading higher by 0.34% at $139.67 premarket on the last check Wednesday.

Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Total
0
Shares
Related Posts
Read More

US Stock Futures Lower Following Friday’s Rally; Tesla In Focus

Pre-open movers U.S. stock futures traded lower in early pre-market trade on Monday after recording sharp gains in the previous session. The Dow Jones jumped by around 750 points on Friday. All the three major indices recorded their best week since June, with the S&P 500 and Dow adding 4.7% and 4.9%, respectively last week.

AVEO

Read More

Elicio Therapeutics To Present Updated Clinical T Cell And Antigen Spreading Response Data From The Ongoing AMPLIFY-201 Phase 1 Study Of ELI-002 And Preclinical Data On ELI-007 And ELI-008 At The AACR Annual Meeting

68% of patients treated with ELI-002 developed cytotoxic mKRAS-specific CD4+ T cells 84% of patients treated with ELI-002 developed cytotoxic mKRAS-specific CD8+ T cellsThe majority of ELI-002-treated patients

ELTX